CLAIM CARD
The most sustained clinical support comes from the Alehagen RCT program, which randomized elderly Swedish citizens to selenium (200 µg) plus CoQ10 (200 mg) or placebo for four years. At the 10-year follow-up, cardiovascular mortality was significantly lower in the active arm (Alehagen 2015: P = 0.0003 for CV mortality). A 12-year post-hoc follow-up confirmed the durability of this effect, with the supplementation group showing persistently reduced cardiovascular mortality (Alehagen 2018: P = 0.001). These data represent the strongest direct clinical RCT evidence for a CoQ10-related longevity benefit.
Evidence grade: exploratory
Contradiction status: none
Publication: b8dee5f7-0023-4af5-bacc-446de915555a
Provenance: Derivation Web chain
Citation Support
source_1Xu 2024source_2Spiegeleer 2025source_3Shang 2024source_4Alehagen 2020source_5Phan 2020